**Supplement Table: Comparison of catheterized patients by study period for the intervention and control floors**

|  |
| --- |
| **Intervention Floors** |
|  | Pre-Intervention7/2012 – 9/2012n = 480 (%) | Intervention/Follow-Up 10/2012-12/2013n = 2258 (%) | P-value  |
| Female Sex | 260 (54.2%) | 1296 (57.4%) | .195 |
| Race Caucasian Black Other/Unknown | 259 (54.0%)190 (39.6%)31 (6.4%) | 1180 (52.3%)921 (40.8%)157 (7.0%) | .779 |
| Age – mean (SD) | 54.05 (16.69) | 55.06 (16.75) | .227 |
| Neutropenia | 11 (2.3%) | 45 (2.0%) | .675 |
| Chemotherapy | 22 (4.6%) | 141 (6.2%) | .162 |
| Corticosteroids | 124 (25.8%) | 570 (25.2%) | .787 |
| Line days per admission – median (IQR) | 3 (2–6) | 3 (2-6) | .636 |

|  |
| --- |
| **Control Floors** |
|  | Pre-Intervention7/2012 – 9/2012n = 424 (%) | Intervention/Follow-Up 10/2012-12/2013n = 2008 (%) | P-value  |
| Female Sex | 244 (57.5%) | 1087 (54.1%) | .199 |
| Race Caucasian Black Other/Unknown | 221 (52.1%)175 (41.3%)28 (6.6%) | 1111 (55.3%)751 (37.4%)146 (7.3%) | .324 |
| Age – mean (SD) | 55.02 (17.36) | 55.57 (17.08) | .552 |
| Neutropenia | 10 (2.4%) | 57 (2.8%) | .583 |
| Chemotherapy | 23 (5.4%) | 138 (6.9%) | .276 |
| Corticosteroids | 105 (24.8%) | 492 (24.5%) | .909 |
| Line days per admission – median (IQR) | 4 (2–6) | 3 (2-6) | .396 |

 Note: SD, Standard deviation; IQR, Interquartile range